title: Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer.
abstract: Intravesical administration of Bacillus Calmette-Guerin (BCG) causes a localized cell-mediated immune response. The intensity of this inflammatory response may be gauged by measuring the levels of both interleukin-2 (IL-2) and an inhibitor of interleukin-2 (IL-2-IN) activity in the urine during the hours after a BCG instillation. The levels of urinary IL-2 and IL-2-IN in the sixth week of BCG therapy predicted the subsequent clinical course in a group of 25 patients (P less than 0.01). Measurement of urinary IL-2 and IL-2-IN activity may be used to identify accurately those patients likely to develop a tumor recurrence, thereby sparing them the risk associated with inadequately treated bladder cancer. Since IL-2 and IL-2-IN are competitive with respect to biologic activity, and since relatively high urinary levels of either IL-2 or IL-2-IN activity correlated with a favorable clinical course, the authors conclude that the presence of bioactive IL-2 in urine is not required for the prevention of recurrent superficial bladder cancer.
authors: Department of Surgery, Metropolitan General Hospital, Case Western Reserve University, Cleveland, Ohio.
authors: J D
authors: JD
authors: Fleischmann
authors: Z
authors: Z
authors: Toossi
authors: J J
authors: JJ
authors: Ellner
authors: D B
authors: DB
authors: Wentworth
authors: T L
authors: TL
authors: Ratliff
authors: A L
authors: AL
authors: Imbembo
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000652:urine*; D002278:Carcinoma in Situ / Q000601:surgery / Q000628:therapy / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000601:surgery / Q000628:therapy / Q000652:urine*; D003131:Combined Modality Therapy; D006801:Humans; D007249:Inflammation; D007376:Interleukin-2 / Q000652:urine*; D008222:Lymphokines / Q000652:urine*; D009363:Neoplasm Proteins / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000601:surgery / Q000628:therapy / Q000652:urine*
chemical_list: D001500:BCG Vaccine; D014408:Biomarkers, Tumor; D007376:Interleukin-2; D008222:Lymphokines; D009363:Neoplasm Proteins; C046147:interleukin 2 inhibitor